Androxal - Is Anyone Familiar with this?

[Guest guest]

Gents

In doing my daily health news reading, I came across the following announcement

about a new drug which supposedly benefits our group. (See link and story

below) - Is anyone familiar with this? Is this the next 'magic bullet'? Have

never heard of it before.

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

Repros receives US patent for Androxal

11. August 2010 07:05

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced the US Patent and

Trademark office has issued U.S. Patent No. 7,759,360 for Androxal®, the

Company's lead program for the treatment of low testosterone in men. This patent

specifically claims methods and materials for the treatment of testosterone

deficiency in men with secondary hypogonadism. Repros has over 35 issued or

pending US and European patents involving Androxal. The term of the patent will

expire on March 19, 2023. If a Patent Term Extension under the Hatch-Waxman Act

is granted, patent life in the US could extend into 2028.

" This patent is important to the protection of our Androxal program. If Repros

can successfully develop Androxal, it could become a leading treatment for low

testosterone in men. "

" We are pleased to strengthen our intellectual property portfolio and expect

additional patent grants surrounding Androxal, " stated ph Podolski,

President and Chief Executive Officer of Repros Therapeutics. " This patent is

important to the protection of our Androxal program. If Repros can successfully

develop Androxal, it could become a leading treatment for low testosterone in

men. "

Androxal is an oral therapy that restores testicular function in men

experiencing low testosterone due to secondary hypogonadism. Secondary

hypogonadism is a condition commonly related to aging but may result or be a co

morbid state associated with a variety of conditions, including Type II

diabetes. Secondary hypogonadism is not a failure of the testes, but an

inability of the pituitary to respond to a low testosterone state by secreting

sufficient levels of luteinizing hormone (LH) to adequately stimulate the

testes. Androxal stimulates the pituitary to secret normal levels of important

testicular stimulating pituitary hormones.

Secondary hypogonadism is the most common cause of low testosterone amongst

American males. Unlike the topical creams and gels Androxal does not suppress

pituitary secretions of LH and FSH (follicle stimulating hormone). Topical

testosterone suppresses fertility. Androxal enhances production of both

testosterone and sperm. Unlike approved topical testosterone treatments,

unwanted transfer of testosterone to women and children is not possible. Since,

in the case of Androxal, pituitary regulation is still intact, supernormal

levels of testosterone are not achieved. In an exploratory efficacy and safety

study in Androxal conducted in 2009, Repros showed that Androxal restores normal

sperm counts while increasing testosterone levels in hypogonadal men.

On Monday, August 9, 2010, Repros announced that the FDA agreed with the

Company's proposal to conduct two Phase III placebo and active controlled

studies in order to demonstrate the benefit of Androxal in normalizing

testosterone levels while preserving fertility.

Source Repros Therapeutics Inc.

[Guest guest]

If your Secondary and have low T due to a bad Pituitary or your brain is shut

down from Steroid use this new drug might be the magic bullet. I can't wate to

try it and I hope is works with out the side like Clomid has this drug is much

like Clomid.

Co-Moderator

Phil

> From: txmtnboy <txmtnboy@...>

> Subject: Androxal - Is Anyone Familiar with this?

>

> Date: Wednesday, August 11, 2010, 10:58 AM

> Gents

>

> In doing my daily health news reading, I came across the

> following announcement about a new drug which supposedly

> benefits our group.  (See link and story below) - Is

> anyone familiar with this?  Is this the next 'magic

> bullet'?  Have never heard of it before.

>

>

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

>

> Repros receives US patent for Androxal

> 11. August 2010 07:05

>

>

> Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced

> the US Patent and Trademark office has issued U.S. Patent

> No. 7,759,360 for Androxal®, the Company's lead program for

> the treatment of low testosterone in men. This patent

> specifically claims methods and materials for the treatment

> of testosterone deficiency in men with secondary

> hypogonadism. Repros has over 35 issued or pending US and

> European patents involving Androxal. The term of the patent

> will expire on March 19, 2023. If a Patent Term Extension

> under the Hatch-Waxman Act is granted, patent life in the US

> could extend into 2028.

> " This patent is important to the protection of our Androxal

> program. If Repros can successfully develop Androxal, it

> could become a leading treatment for low testosterone in

> men. "

>

> " We are pleased to strengthen our intellectual property

> portfolio and expect additional patent grants surrounding

> Androxal, " stated ph Podolski, President and Chief

> Executive Officer of Repros Therapeutics. " This patent is

> important to the protection of our Androxal program. If

> Repros can successfully develop Androxal, it could become a

> leading treatment for low testosterone in men. "

> Androxal is an oral therapy that restores testicular

> function in men experiencing low testosterone due to

> secondary hypogonadism. Secondary hypogonadism is a

> condition commonly related to aging but may result or be a

> co morbid state associated with a variety of conditions,

> including Type II diabetes. Secondary hypogonadism is not a

> failure of the testes, but an inability of the pituitary to

> respond to a low testosterone state by secreting sufficient

> levels of luteinizing hormone (LH) to adequately stimulate

> the testes. Androxal stimulates the pituitary to secret

> normal levels of important testicular stimulating pituitary

> hormones.

>

> Secondary hypogonadism is the most common cause of low

> testosterone amongst American males. Unlike the topical

> creams and gels Androxal does not suppress pituitary

> secretions of LH and FSH (follicle stimulating hormone).

> Topical testosterone suppresses fertility. Androxal enhances

> production of both testosterone and sperm. Unlike approved

> topical testosterone treatments, unwanted transfer of

> testosterone to women and children is not possible. Since,

> in the case of Androxal, pituitary regulation is still

> intact, supernormal levels of testosterone are not achieved.

> In an exploratory efficacy and safety study in Androxal

> conducted in 2009, Repros showed that Androxal restores

> normal sperm counts while increasing testosterone levels in

> hypogonadal men.

>

> On Monday, August 9, 2010, Repros announced that the FDA

> agreed with the Company's proposal to conduct two Phase III

> placebo and active controlled studies in order to

> demonstrate the benefit of Androxal in normalizing

> testosterone levels while preserving fertility.

> Source Repros Therapeutics Inc.

>

>

>

>

>

> ------------------------------------

>

>

[Guest guest]

I hope this will help all of us so we all dont have to take all these shots etc

JOe

>

> > From: txmtnboy <txmtnboy@...>

> > Subject: Androxal - Is Anyone Familiar with this?

> >

> > Date: Wednesday, August 11, 2010, 10:58 AM

> > Gents

> >

> > In doing my daily health news reading, I came across the

> > following announcement about a new drug which supposedly

> > benefits our group.  (See link and story below) - Is

> > anyone familiar with this?  Is this the next 'magic

> > bullet'?  Have never heard of it before.

> >

> >

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

> >

> > Repros receives US patent for Androxal

> > 11. August 2010 07:05

> >

> >

> > Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced

> > the US Patent and Trademark office has issued U.S. Patent

> > No. 7,759,360 for Androxal®, the Company's lead program for

> > the treatment of low testosterone in men. This patent

> > specifically claims methods and materials for the treatment

> > of testosterone deficiency in men with secondary

> > hypogonadism. Repros has over 35 issued or pending US and

> > European patents involving Androxal. The term of the patent

> > will expire on March 19, 2023. If a Patent Term Extension

> > under the Hatch-Waxman Act is granted, patent life in the US

> > could extend into 2028.

> > " This patent is important to the protection of our Androxal

> > program. If Repros can successfully develop Androxal, it

> > could become a leading treatment for low testosterone in

> > men. "

> >

> > " We are pleased to strengthen our intellectual property

> > portfolio and expect additional patent grants surrounding

> > Androxal, " stated ph Podolski, President and Chief

> > Executive Officer of Repros Therapeutics. " This patent is

> > important to the protection of our Androxal program. If

> > Repros can successfully develop Androxal, it could become a

> > leading treatment for low testosterone in men. "

> > Androxal is an oral therapy that restores testicular

> > function in men experiencing low testosterone due to

> > secondary hypogonadism. Secondary hypogonadism is a

> > condition commonly related to aging but may result or be a

> > co morbid state associated with a variety of conditions,

> > including Type II diabetes. Secondary hypogonadism is not a

> > failure of the testes, but an inability of the pituitary to

> > respond to a low testosterone state by secreting sufficient

> > levels of luteinizing hormone (LH) to adequately stimulate

> > the testes. Androxal stimulates the pituitary to secret

> > normal levels of important testicular stimulating pituitary

> > hormones.

> >

> > Secondary hypogonadism is the most common cause of low

> > testosterone amongst American males. Unlike the topical

> > creams and gels Androxal does not suppress pituitary

> > secretions of LH and FSH (follicle stimulating hormone).

> > Topical testosterone suppresses fertility. Androxal enhances

> > production of both testosterone and sperm. Unlike approved

> > topical testosterone treatments, unwanted transfer of

> > testosterone to women and children is not possible. Since,

> > in the case of Androxal, pituitary regulation is still

> > intact, supernormal levels of testosterone are not achieved.

> > In an exploratory efficacy and safety study in Androxal

> > conducted in 2009, Repros showed that Androxal restores

> > normal sperm counts while increasing testosterone levels in

> > hypogonadal men.

> >

> > On Monday, August 9, 2010, Repros announced that the FDA

> > agreed with the Company's proposal to conduct two Phase III

> > placebo and active controlled studies in order to

> > demonstrate the benefit of Androxal in normalizing

> > testosterone levels while preserving fertility.

> > Source Repros Therapeutics Inc.

> >

> >

> >

> >

> >

> > ------------------------------------

> >

> >

[Guest guest]

Androxal has been in testing for at least six years. It is a derivative of

clomiphene and I wouldn't expect to see it on the market for at least another

couple of years.

>

> > From: txmtnboy <txmtnboy@...>

> > Subject: Androxal - Is Anyone Familiar with this?

> >

> > Date: Wednesday, August 11, 2010, 10:58 AM

> > Gents

> >

> > In doing my daily health news reading, I came across the

> > following announcement about a new drug which supposedly

> > benefits our group.  (See link and story below) - Is

> > anyone familiar with this?  Is this the next 'magic

> > bullet'?  Have never heard of it before.

> >

> >

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

> >

> > Repros receives US patent for Androxal

> > 11. August 2010 07:05

> >

> >

> > Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced

> > the US Patent and Trademark office has issued U.S. Patent

> > No. 7,759,360 for Androxal®, the Company's lead program for

> > the treatment of low testosterone in men. This patent

> > specifically claims methods and materials for the treatment

> > of testosterone deficiency in men with secondary

> > hypogonadism. Repros has over 35 issued or pending US and

> > European patents involving Androxal. The term of the patent

> > will expire on March 19, 2023. If a Patent Term Extension

> > under the Hatch-Waxman Act is granted, patent life in the US

> > could extend into 2028.

> > " This patent is important to the protection of our Androxal

> > program. If Repros can successfully develop Androxal, it

> > could become a leading treatment for low testosterone in

> > men. "

> >

> > " We are pleased to strengthen our intellectual property

> > portfolio and expect additional patent grants surrounding

> > Androxal, " stated ph Podolski, President and Chief

> > Executive Officer of Repros Therapeutics. " This patent is

> > important to the protection of our Androxal program. If

> > Repros can successfully develop Androxal, it could become a

> > leading treatment for low testosterone in men. "

> > Androxal is an oral therapy that restores testicular

> > function in men experiencing low testosterone due to

> > secondary hypogonadism. Secondary hypogonadism is a

> > condition commonly related to aging but may result or be a

> > co morbid state associated with a variety of conditions,

> > including Type II diabetes. Secondary hypogonadism is not a

> > failure of the testes, but an inability of the pituitary to

> > respond to a low testosterone state by secreting sufficient

> > levels of luteinizing hormone (LH) to adequately stimulate

> > the testes. Androxal stimulates the pituitary to secret

> > normal levels of important testicular stimulating pituitary

> > hormones.

> >

> > Secondary hypogonadism is the most common cause of low

> > testosterone amongst American males. Unlike the topical

> > creams and gels Androxal does not suppress pituitary

> > secretions of LH and FSH (follicle stimulating hormone).

> > Topical testosterone suppresses fertility. Androxal enhances

> > production of both testosterone and sperm. Unlike approved

> > topical testosterone treatments, unwanted transfer of

> > testosterone to women and children is not possible. Since,

> > in the case of Androxal, pituitary regulation is still

> > intact, supernormal levels of testosterone are not achieved.

> > In an exploratory efficacy and safety study in Androxal

> > conducted in 2009, Repros showed that Androxal restores

> > normal sperm counts while increasing testosterone levels in

> > hypogonadal men.

> >

> > On Monday, August 9, 2010, Repros announced that the FDA

> > agreed with the Company's proposal to conduct two Phase III

> > placebo and active controlled studies in order to

> > demonstrate the benefit of Androxal in normalizing

> > testosterone levels while preserving fertility.

> > Source Repros Therapeutics Inc.

> >

> >

> >

> >

> >

> > ------------------------------------

> >

> >

[Guest guest]

My limited knowledge of oral TRT is that it's hard on the liver.  A doc on this

board should be able to give you some insight if this drug is worth looking at.

________________________________

From: txmtnboy <txmtnboy@...>

Sent: Wed, August 11, 2010 10:58:21 AM

Subject: Androxal - Is Anyone Familiar with this?

 

Gents

In doing my daily health news reading, I came across the following announcement

about a new drug which supposedly benefits our group. (See link and story below)

- Is anyone familiar with this? Is this the next 'magic bullet'? Have never

heard of it before.

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

Repros receives US patent for Androxal

11. August 2010 07:05

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced the US Patent and

Trademark office has issued U.S. Patent No. 7,759,360 for Androxal®, the

Company's lead program for the treatment of low testosterone in men. This patent

specifically claims methods and materials for the treatment of testosterone

deficiency in men with secondary hypogonadism. Repros has over 35 issued or

pending US and European patents involving Androxal. The term of the patent will

expire on March 19, 2023. If a Patent Term Extension under the Hatch-Waxman Act

is granted, patent life in the US could extend into 2028.

" This patent is important to the protection of our Androxal program. If Repros

can successfully develop Androxal, it could become a leading treatment for low

testosterone in men. "

" We are pleased to strengthen our intellectual property portfolio and expect

additional patent grants surrounding Androxal, " stated ph Podolski,

President and Chief Executive Officer of Repros Therapeutics. " This patent is

important to the protection of our Androxal program. If Repros can successfully

develop Androxal, it could become a leading treatment for low testosterone in

men. "

Androxal is an oral therapy that restores testicular function in men

experiencing low testosterone due to secondary hypogonadism. Secondary

hypogonadism is a condition commonly related to aging but may result or be a co

morbid state associated with a variety of conditions, including Type II

diabetes. Secondary hypogonadism is not a failure of the testes, but an

inability of the pituitary to respond to a low testosterone state by secreting

sufficient levels of luteinizing hormone (LH) to adequately stimulate the

testes. Androxal stimulates the pituitary to secret normal levels of important

testicular stimulating pituitary hormones.

Secondary hypogonadism is the most common cause of low testosterone amongst

American males. Unlike the topical creams and gels Androxal does not suppress

pituitary secretions of LH and FSH (follicle stimulating hormone). Topical

testosterone suppresses fertility. Androxal enhances production of both

testosterone and sperm. Unlike approved topical testosterone treatments,

unwanted transfer of testosterone to women and children is not possible. Since,

in the case of Androxal, pituitary regulation is still intact, supernormal

levels of testosterone are not achieved. In an exploratory efficacy and safety

study in Androxal conducted in 2009, Repros showed that Androxal restores normal

sperm counts while increasing testosterone levels in hypogonadal men.

On Monday, August 9, 2010, Repros announced that the FDA agreed with the

Company's proposal to conduct two Phase III placebo and active controlled

studies in order to demonstrate the benefit of Androxal in normalizing

testosterone levels while preserving fertility.

Source Repros Therapeutics Inc.

[Guest guest]

There is a oral gel cap out now called " Andriol " that is supposed 2 bypass the

liver and isn't very hard on it at all..

>

> My limited knowledge of oral TRT is that it's hard on the liver.  A doc on

this

> board should be able to give you some insight if this drug is worth looking

at.

>

>

>

>

> ________________________________

> From: txmtnboy <txmtnboy@...>

>

> Sent: Wed, August 11, 2010 10:58:21 AM

> Subject: Androxal - Is Anyone Familiar with this?

>

>  

> Gents

>

> In doing my daily health news reading, I came across the following

announcement

> about a new drug which supposedly benefits our group. (See link and story

below)

> - Is anyone familiar with this? Is this the next 'magic bullet'? Have never

> heard of it before.

>

>

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

>

>

> Repros receives US patent for Androxal

> 11. August 2010 07:05

>

> Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced the US Patent and

> Trademark office has issued U.S. Patent No. 7,759,360 for Androxal®, the

> Company's lead program for the treatment of low testosterone in men. This

patent

> specifically claims methods and materials for the treatment of testosterone

> deficiency in men with secondary hypogonadism. Repros has over 35 issued or

> pending US and European patents involving Androxal. The term of the patent

will

> expire on March 19, 2023. If a Patent Term Extension under the Hatch-Waxman

Act

> is granted, patent life in the US could extend into 2028.

>

> " This patent is important to the protection of our Androxal program. If Repros

> can successfully develop Androxal, it could become a leading treatment for low

> testosterone in men. "

>

> " We are pleased to strengthen our intellectual property portfolio and expect

> additional patent grants surrounding Androxal, " stated ph Podolski,

> President and Chief Executive Officer of Repros Therapeutics. " This patent is

> important to the protection of our Androxal program. If Repros can

successfully

> develop Androxal, it could become a leading treatment for low testosterone in

> men. "

>

> Androxal is an oral therapy that restores testicular function in men

> experiencing low testosterone due to secondary hypogonadism. Secondary

> hypogonadism is a condition commonly related to aging but may result or be a

co

> morbid state associated with a variety of conditions, including Type II

> diabetes. Secondary hypogonadism is not a failure of the testes, but an

> inability of the pituitary to respond to a low testosterone state by secreting

> sufficient levels of luteinizing hormone (LH) to adequately stimulate the

> testes. Androxal stimulates the pituitary to secret normal levels of important

> testicular stimulating pituitary hormones.

>

>

> Secondary hypogonadism is the most common cause of low testosterone amongst

> American males. Unlike the topical creams and gels Androxal does not suppress

> pituitary secretions of LH and FSH (follicle stimulating hormone). Topical

> testosterone suppresses fertility. Androxal enhances production of both

> testosterone and sperm. Unlike approved topical testosterone treatments,

> unwanted transfer of testosterone to women and children is not possible.

Since,

> in the case of Androxal, pituitary regulation is still intact, supernormal

> levels of testosterone are not achieved. In an exploratory efficacy and safety

> study in Androxal conducted in 2009, Repros showed that Androxal restores

normal

> sperm counts while increasing testosterone levels in hypogonadal men.

>

>

> On Monday, August 9, 2010, Repros announced that the FDA agreed with the

> Company's proposal to conduct two Phase III placebo and active controlled

> studies in order to demonstrate the benefit of Androxal in normalizing

> testosterone levels while preserving fertility.

>

> Source Repros Therapeutics Inc.

>

>

>

>

>

>

>

>

[Guest guest]

Androxal is not a testosterone pill it's a pill that makes your Pituitary tell

your testis to make more T by sending them more LH and FSH the message that

tells testis to make T.

Yes your right Testosterone pills are hard or bad for ones liver but Androxal is

not a T pill.

Co-Moderator

Phil

> From: Bill Totten <bill_totten@...>

> Subject: Re: Androxal - Is Anyone Familiar with this?

>

> Date: Thursday, August 12, 2010, 8:33 AM

> My limited knowledge of oral TRT is

> that it's hard on the liver.  A doc on this

> board should be able to give you some insight if this drug

> is worth looking at.

>

>

>

>

> ________________________________

> From: txmtnboy <txmtnboy@...>

>

> Sent: Wed, August 11, 2010 10:58:21 AM

> Subject: Androxal - Is Anyone Familiar with

> this?

>

>  

> Gents

>

> In doing my daily health news reading, I came across the

> following announcement

> about a new drug which supposedly benefits our group. (See

> link and story below)

> - Is anyone familiar with this? Is this the next 'magic

> bullet'? Have never

> heard of it before.

>

>

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

>

>

> Repros receives US patent for Androxal

> 11. August 2010 07:05

>

> Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced

> the US Patent and

> Trademark office has issued U.S. Patent No. 7,759,360 for

> Androxal®, the

> Company's lead program for the treatment of low

> testosterone in men. This patent

> specifically claims methods and materials for the treatment

> of testosterone

> deficiency in men with secondary hypogonadism. Repros has

> over 35 issued or

> pending US and European patents involving Androxal. The

> term of the patent will

> expire on March 19, 2023. If a Patent Term Extension under

> the Hatch-Waxman Act

> is granted, patent life in the US could extend into 2028.

>

> " This patent is important to the protection of our Androxal

> program. If Repros

> can successfully develop Androxal, it could become a

> leading treatment for low

> testosterone in men. "

>

> " We are pleased to strengthen our intellectual property

> portfolio and expect

> additional patent grants surrounding Androxal, " stated

> ph Podolski,

> President and Chief Executive Officer of Repros

> Therapeutics. " This patent is

> important to the protection of our Androxal program. If

> Repros can successfully

> develop Androxal, it could become a leading treatment for

> low testosterone in

> men. "

>

> Androxal is an oral therapy that restores testicular

> function in men

> experiencing low testosterone due to secondary

> hypogonadism. Secondary

> hypogonadism is a condition commonly related to aging but

> may result or be a co

> morbid state associated with a variety of conditions,

> including Type II

> diabetes. Secondary hypogonadism is not a failure of the

> testes, but an

> inability of the pituitary to respond to a low testosterone

> state by secreting

> sufficient levels of luteinizing hormone (LH) to adequately

> stimulate the

> testes. Androxal stimulates the pituitary to secret normal

> levels of important

> testicular stimulating pituitary hormones.

>

>

> Secondary hypogonadism is the most common cause of low

> testosterone amongst

> American males. Unlike the topical creams and gels Androxal

> does not suppress

> pituitary secretions of LH and FSH (follicle stimulating

> hormone). Topical

> testosterone suppresses fertility. Androxal enhances

> production of both

> testosterone and sperm. Unlike approved topical

> testosterone treatments,

> unwanted transfer of testosterone to women and children is

> not possible. Since,

> in the case of Androxal, pituitary regulation is still

> intact, supernormal

> levels of testosterone are not achieved. In an exploratory

> efficacy and safety

> study in Androxal conducted in 2009, Repros showed that

> Androxal restores normal

> sperm counts while increasing testosterone levels in

> hypogonadal men.

>

>

> On Monday, August 9, 2010, Repros announced that the FDA

> agreed with the

> Company's proposal to conduct two Phase III placebo and

> active controlled

> studies in order to demonstrate the benefit of Androxal in

> normalizing

> testosterone levels while preserving fertility.

>

> Source Repros Therapeutics Inc.

>

>

>

>

>

>      

>

>

[Guest guest]

That is the problem with it " supposed 2 bypass the liver " I for one don't want

to try it.

Co-Moderator

Phil

> From: threefingers_in_the_box <no_reply >

> Subject: Re: Androxal - Is Anyone Familiar with this?

>

> Date: Thursday, August 12, 2010, 10:27 AM

> There is a oral gel cap out now

> called " Andriol " that is supposed 2 bypass the liver and

> isn't very hard on it at all..

>

>

> >

> > My limited knowledge of oral TRT is that it's hard on

> the liver.  A doc on this

> > board should be able to give you some insight if this

> drug is worth looking at.

> >

> >

> >

> >

> > ________________________________

> > From: txmtnboy <txmtnboy@...>

> >

> > Sent: Wed, August 11, 2010 10:58:21 AM

> > Subject: Androxal - Is Anyone Familiar

> with this?

> >

> >  

> > Gents

> >

> > In doing my daily health news reading, I came across

> the following announcement

> > about a new drug which supposedly benefits our group.

> (See link and story below)

> > - Is anyone familiar with this? Is this the next

> 'magic bullet'? Have never

> > heard of it before.

> >

> >

http://www.news-medical.net/news/20100811/Repros-receives-US-patent-for-Androxal\

..aspx

> >

> >

> > Repros receives US patent for Androxal

> > 11. August 2010 07:05

> >

> > Repros Therapeutics Inc. (NasdaqCM:RPRX) today

> announced the US Patent and

> > Trademark office has issued U.S. Patent No. 7,759,360

> for Androxal®, the

> > Company's lead program for the treatment of low

> testosterone in men. This patent

> > specifically claims methods and materials for the

> treatment of testosterone

> > deficiency in men with secondary hypogonadism. Repros

> has over 35 issued or

> > pending US and European patents involving Androxal.

> The term of the patent will

> > expire on March 19, 2023. If a Patent Term Extension

> under the Hatch-Waxman Act

> > is granted, patent life in the US could extend into

> 2028.

> >

> > " This patent is important to the protection of our

> Androxal program. If Repros

> > can successfully develop Androxal, it could become a

> leading treatment for low

> > testosterone in men. "

> >

> > " We are pleased to strengthen our intellectual

> property portfolio and expect

> > additional patent grants surrounding Androxal, " stated

> ph Podolski,

> > President and Chief Executive Officer of Repros

> Therapeutics. " This patent is

> > important to the protection of our Androxal program.

> If Repros can successfully

> > develop Androxal, it could become a leading treatment

> for low testosterone in

> > men. "

> >

> > Androxal is an oral therapy that restores testicular

> function in men

> > experiencing low testosterone due to secondary

> hypogonadism. Secondary

> > hypogonadism is a condition commonly related to aging

> but may result or be a co

> > morbid state associated with a variety of conditions,

> including Type II

> > diabetes. Secondary hypogonadism is not a failure of

> the testes, but an

> > inability of the pituitary to respond to a low

> testosterone state by secreting

> > sufficient levels of luteinizing hormone (LH) to

> adequately stimulate the

> > testes. Androxal stimulates the pituitary to secret

> normal levels of important

> > testicular stimulating pituitary hormones.

> >

> >

> > Secondary hypogonadism is the most common cause of low

> testosterone amongst

> > American males. Unlike the topical creams and gels

> Androxal does not suppress

> > pituitary secretions of LH and FSH (follicle

> stimulating hormone). Topical

> > testosterone suppresses fertility. Androxal enhances

> production of both

> > testosterone and sperm. Unlike approved topical

> testosterone treatments,

> > unwanted transfer of testosterone to women and

> children is not possible. Since,

> > in the case of Androxal, pituitary regulation is still

> intact, supernormal

> > levels of testosterone are not achieved. In an

> exploratory efficacy and safety

> > study in Androxal conducted in 2009, Repros showed

> that Androxal restores normal

> > sperm counts while increasing testosterone levels in

> hypogonadal men.

> >

> >

> > On Monday, August 9, 2010, Repros announced that the

> FDA agreed with the

> > Company's proposal to conduct two Phase III placebo

> and active controlled

> > studies in order to demonstrate the benefit of

> Androxal in normalizing

> > testosterone levels while preserving fertility.

> >

> > Source Repros Therapeutics Inc.

> >

> >

> >

> >

> >

> >       

> >

> >